Company / Total Debt
Bristol Myers Squibb Total Debt History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Debt
$44.8B
FY2025
5-year range
$39.0B / $49.4B
FY2021-FY2025
Trend
-9.3%
vs FY2024
Sector context
#5 of 83
Health Care
What the data says
Among 83 Health Care companies, Bristol Myers Squibb is in the bottom 6% for total debt. Total Debt has fluctuated over the past 10 years, ranging from $5.6B in FY2019 to $50.3B in FY2020.
Based on SEC 10-K filings.
$44.8B in FY2025 with a 5-year CAGR of -2.3%. Top quartile in the Health Care sector.
Increased from $39.5B to $44.8B over the past 2 years.
Health Care sector context is included.
Total Debt over time
Growth rates
- 3-Year CAGR
- +4.8%
- 5-Year CAGR
- -2.3%
- 10-Year CAGR
- -
Sector benchmark
Bottom 6% in Health CareTop 94% of 83This company $44.8B Sector average $6.2B
▼
+628.7% above sector average
Key checks
Key Insights
- 5-year CAGR of -2.3%, indicating a declining trend.
- In FY2025, total debt decreased 9.3% year-over-year.
- Ranks #5 out of 83 companies in the Health Care sector.
- Peak total debt was recorded in FY2020.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 0.85 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
- Strong return on equity: 32.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total DebtValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $44.8B | -9.3% |
| FY2024 | $49.4B | +25.1% |
| FY2023 | $39.5B | +1.5% |
| FY2022 | $39.0B | -12.2% |
| FY2021 | $44.4B | -11.9% |
| FY2020 | $50.3B | +793.3% |
| FY2019 | $5.6B | -2.4% |
| FY2018 | $5.8B | -20.2% |
| FY2017 | $7.2B | +26.6% |
| FY2016 | $5.7B | -12.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026